Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: Clinical course and outcomes

References

• Wang TY, Ou FS, Roe MT, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation 2009; 119: 2454–2462
   PubMed Web of Science ®Google Scholar
• Matthai WH, Jr. Thrombocytopenia in cardiovascular patients: Diagnosis and management. Chest 2005; 127: 46S–52S
   PubMed Web of Science ®Google Scholar
• Cornet AD, Klein LJ, Groeneveld AB. Coronary stent occlusion after platelet transfusion: A case series. J Invasive Cardiol 2007; 19: E297–E299
   Google Scholar
• Vamvakas EC. Platelet transfusion and adverse outcomes. Lancet 2004; 364: 1736–1738
   PubMedGoogle Scholar
• Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003; 41: 26–32
   PubMed Web of Science ®Google Scholar
• Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE, Kandzari DE, Topol EJ, Califf RM. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003; 92: 651–655
   PubMed Web of Science ®Google Scholar
• Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol 2007; 23: 963–970
   PubMedGoogle Scholar
• Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100: 2071–2076
   PubMed Web of Science ®Google Scholar
• Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006; 97: 426–429
   PubMed Web of Science ®Google Scholar
• Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004; 109: 2203–2206
   PubMed Web of Science ®Google Scholar
• Coller BS. Anti-GPIIb/IIIa drugs: Current strategies and future directions. Thromb Haemost 2001; 86: 427–443
   PubMed Web of Science ®Google Scholar
• Overgaard CB, Ivanov J, Seidelin PH, Todorov M, Mackie K, Dzavik V. Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention. Am Heart J 2008; 156: 120–124
   PubMed Web of Science ®Google Scholar
• Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142–154
   PubMed Web of Science ®Google Scholar
• Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: A nuisance in both bare metal and drug-eluting stents. Circulation 2007; 115: 1433–1439, discussion 1439
   PubMed Web of Science ®Google Scholar
• Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2004; 1–39, CD004269
   Google Scholar
• Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580–587
   PubMed Web of Science ®Google Scholar
• Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation. 2004; 109: 2203–2206
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Berkowitz SD, Lincoff AM, Tcheng JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000; 140: 74–80
   PubMed Web of Science ®Google Scholar
• Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409–417
   PubMed Web of Science ®Google Scholar
• Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555–1562
   PubMed Web of Science ®Google Scholar
• Chun R, Orser BA, Madan M. Platelet glycoprotein IIb/IIIa inhibitors: Overview and implications for the anesthesiologist. Anesth Analg 2002; 95: 879–888
   PubMed Web of Science ®Google Scholar
• Giugliano RP. Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors?. J Thromb Thrombolysis 1998; 5: 191–202
   PubMed Web of Science ®Google Scholar
• Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999; 6: 437–441
   PubMedGoogle Scholar
• Said SM, Hahn J, Schleyer E, Muller M, Fiedler GM, Buerke M, Prondzinsky R. Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: Diagnosis and treatment. Clin Res Cardiol 2007; 96: 61–69
   PubMed Web of Science ®Google Scholar
• Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: Diagnosis and management update. Postgrad Med J 2007; 83: 575–582
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Crowther MA. Adverse prognostic significance of thrombocytopenia in acute coronary syndrome: Can anything be done about it?. Circulation 2009; 119: 2420–2422
   PubMedGoogle Scholar